v3.23.3
Consolidated Statements of Cash Flows - USD ($)
 9 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Cash flows from operating activities:        
Net loss $ (7,121,914) $ (18,729,609) $ (24,207,685) $ (29,145,901)
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation     151
Gain on sale of asset (4,500) (4,500)
Accrued interest 9,146 57,536 60,488 349,339
Accretion of discounts on promissory notes     945,969
Change in fair value of derivative liability     (673,314)
Change in fair value of convertible notes (146,479) (6,169,929) (5,756,787) 2,993,060
Loss on issuance of convertible notes 3,609,944 3,609,944
Loss on extinguishment of debt     347,566
Stock-based compensation 250,224 855,160 1,071,843 121,764
Issuance of liability classified warrants 3,737,371 3,737,371 1,865,403
Change in fair value of liability classified warrants (279,873) (5,626,130) (6,730,613) 1,438,186
Issuance of warrants for share subscription facility     11,565,472
Commitment fee for share subscription facility     1,124,289
Warrant modification     56,590
Lease cost (135) (63) (3) (1,808)
Issuance costs paid to close convertible notes 946,085 946,085 1,920,158
Loss on debt conversions 4,000,155 3,964,633 154,391
Other income     (60,035)
Changes in operating assets and liabilities:        
Unbilled receivable 169,083 300,908 164,900 (441,721)
Prepaid expenses and other assets 1,235,252 475,499 1,652,756 (1,616,019)
Accounts payable (2,027,375) 984,410 2,642,686 (1,423,494)
Accrued expenses and other liabilities (1,066,036) 971,344 1,021,478 2,177,742
Net cash used in operating activities (8,978,107) (14,591,819) (17,887,439) (8,242,177)
Cash flows from investing activities:        
Proceeds from sale of asset 4,500 4,500
Net cash provided by investing activities 4,500 4,500
Cash flows from financing activities:        
Proceeds public offerings, net 9,050,004 3,783,240
Proceeds from issuance of convertible notes, net 7,533,915 7,533,915 14,029,842
Proceeds from issuance of promissory notes to related parties     350,000
Repayments of convertible notes (1,000,208) (265,812) (1,408,364)  
Repayment of promissory notes     (467,774)
Transaction costs associated with public offerings (447,879) (547,377)  
Proceeds from exercise of stock options     262,862
Proceeds from issuance of common stock for business combination, net of transaction costs     6,626,312
Repayment of financed insurance premiums (307,131) (442,439) (595,509) (488,543)
Net cash provided by financing activities 7,294,786 6,825,664 8,765,905 20,312,699
Decrease in cash and cash equivalents (1,683,321) (7,761,655) (9,117,034) 12,070,522
Cash and cash equivalents beginning of period 3,147,702 12,264,736 12,264,736 194,214
Cash and cash equivalents end of period 1,464,381 4,503,081 3,147,702 12,264,736
Supplemental cash flow information:        
Income tax payments 1,600 1,600 1,600
Supplemental disclosure of non-cash investing and financing activities:        
Stock-based compensation 1,742,478 1,742,481
Conversions of convertible notes into common stock 3,056,892 13,879,535 3,056,892 13,879,535
Payable to related parties 800,000 800,000
Proceeds from financed insurance premiums, net 445,737 399,949 445,738 399,949
Settlement of commitment fee in shares 400,000 400,000
Fair value of derivative liability at issuance     3,052
Settlement of convertible notes into common stock     17,521,271 7,789,927
Payable to related parties settled in shares     191,618
Capital contribution from related parties     608,382
Net assets acquired in business combination     1,068,950
Financed insurance premiums     399,949 867,300
Share subscription facility transaction costs     12,689,764
Deemed dividend related to warrants down round provision $ 12,038 $ 881,598 $ 913,204 $ 803,140